UNLABELLED: The association of cyclophosphamide (CYC) and prednisone (PRED) for the treatment of lung fibrosis in systemic sclerosis (SSc) was only evaluated in uncontrolled studies, although in idiopathic interstitial lung disease (ILD) this association seems to be beneficial in patients with non-specific interstitial pneumonia (NSIP). OBJECTIVES: To treat SSc-ILD in a prospective open-label controlled study based on lung pattern during 12 months of treatment. METHODS: A 3-year analysis was also performed. Twenty-four consecutive patients with SSc and ILD were submitted to an open lung biopsy. Eighteen patients (NSIP) were randomized in two groups: CYC versus CYC + PRED during 12 months. Lung function tests (diffusion lung capacity of monoxide carbone corrected for hemoglobin concentration (DLCO-Hb), forced vital capacity (FVC), total lung capacity) and Modified Rodnan Skin Score (MRSS) were performed before, after one of treatment and after 3 years from the end of the treatment. RESULTS:Pulmonary function tests were similar in both groups on baseline. After 1 year of treatment, FVC% was comparable between CYC groups (p = 0.72) and in CYC + PRED (p = 0.40). Three years after the end of treatment, FVC% values (p = 0.39 in group CYC and p = 0.61 in CYC + PRED and p = 0.22 in CYC + PRED) and DLCO-Hb (p = 0.54 in CYC and p = 0.28 in CYC + PRED) were similar compared to 1 year of treatment. We observed a reduction of the MRSS in the CYC + PRED group after 1 year of treatment (p = 0.02); although after 3 years, MRSS values remained stable in both groups. CONCLUSIONS:CYC was effective to stabilize lung function parameters in NSIP lung pattern of SSc disease for 3 years after the end of a 1-year therapy.
RCT Entities:
UNLABELLED: The association of cyclophosphamide (CYC) and prednisone (PRED) for the treatment of lung fibrosis in systemic sclerosis (SSc) was only evaluated in uncontrolled studies, although in idiopathic interstitial lung disease (ILD) this association seems to be beneficial in patients with non-specific interstitial pneumonia (NSIP). OBJECTIVES: To treat SSc-ILD in a prospective open-label controlled study based on lung pattern during 12 months of treatment. METHODS: A 3-year analysis was also performed. Twenty-four consecutive patients with SSc and ILD were submitted to an open lung biopsy. Eighteen patients (NSIP) were randomized in two groups: CYC versus CYC + PRED during 12 months. Lung function tests (diffusion lung capacity of monoxide carbone corrected for hemoglobin concentration (DLCO-Hb), forced vital capacity (FVC), total lung capacity) and Modified Rodnan Skin Score (MRSS) were performed before, after one of treatment and after 3 years from the end of the treatment. RESULTS: Pulmonary function tests were similar in both groups on baseline. After 1 year of treatment, FVC% was comparable between CYC groups (p = 0.72) and in CYC + PRED (p = 0.40). Three years after the end of treatment, FVC% values (p = 0.39 in group CYC and p = 0.61 in CYC + PRED and p = 0.22 in CYC + PRED) and DLCO-Hb (p = 0.54 in CYC and p = 0.28 in CYC + PRED) were similar compared to 1 year of treatment. We observed a reduction of the MRSS in the CYC + PRED group after 1 year of treatment (p = 0.02); although after 3 years, MRSS values remained stable in both groups. CONCLUSIONS:CYC was effective to stabilize lung function parameters in NSIP lung pattern of SSc disease for 3 years after the end of a 1-year therapy.
Authors: A Ludwicka; T Ohba; M Trojanowska; A Yamakage; C Strange; E A Smith; E C Leroy; S Sutherland; R M Silver Journal: J Rheumatol Date: 1995-10 Impact factor: 4.666
Authors: Romy B C de Souza; Claudia T L Borges; Vera L Capelozzi; Edwin R Parra; Fabio B Jatene; Jorge Kavakama; Ronaldo A Kairalla; Eloisa Bonfá Journal: Respiration Date: 2008-09-18 Impact factor: 3.580
Authors: C P Simeón; L Armadans; V Fonollosa; R Solans; A Selva; M Villar; J Lima; J Vaqué; M Vilardell Journal: Rheumatology (Oxford) Date: 2003-01 Impact factor: 7.580
Authors: C P Simeón-Aznar; V Fonollosa-Plá; C Tolosa-Vilella; A Selva-O Callaghan; R Solans-Laqué; E Palliza; X Muñoz; M Vilardell-Tarrés Journal: Open Respir Med J Date: 2008-05-15
Authors: Rajaie Namas; Donald P Tashkin; Daniel E Furst; Holly Wilhalme; Chi-Hong Tseng; Michael D Roth; Suzanne Kafaja; Elizabeth Volkmann; Philip J Clements; Dinesh Khanna Journal: Arthritis Care Res (Hoboken) Date: 2018-02-09 Impact factor: 4.794
Authors: David Roofeh; Shaney L Barratt; Athol U Wells; Leticia Kawano-Dourado; Donald Tashkin; Vibeke Strand; James Seibold; Susanna Proudman; Kevin K Brown; Paul F Dellaripa; Tracy Doyle; Thomas Leonard; Eric L Matteson; Chester V Oddis; Joshua J Solomon; Jeffrey A Sparks; Robert Vassallo; Lara Maxwell; Dorcas Beaton; Robin Christensen; Whitney Townsend; Dinesh Khanna Journal: Semin Arthritis Rheum Date: 2021-08-20 Impact factor: 5.431